EUR 28.02
(-1.06%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 28.93 Million SEK | 155.99% |
2022 | -54.34 Million SEK | 30.91% |
2021 | -72.39 Million SEK | 16.32% |
2020 | -90.09 Million SEK | 38.17% |
2019 | -150.27 Million EUR | 16.73% |
2018 | -172.25 Million EUR | -73.4% |
2017 | -109.7 Million EUR | -6.1% |
2016 | -96.57 Million EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 30.58 Million EUR | -8.25% |
2024 Q3 | 42.83 Million SEK | 35.49% |
2024 Q1 | 2.39 Million SEK | 1518.41% |
2023 FY | - SEK | 155.99% |
2023 Q4 | 645 Thousand SEK | -57.14% |
2023 Q1 | 276.24 Thousand SEK | 123.41% |
2023 Q2 | 287.88 Thousand SEK | 4.21% |
2023 Q3 | 1.5 Million SEK | 422.77% |
2022 Q2 | -1.57 Million EUR | -5.95% |
2022 FY | - SEK | 30.91% |
2022 Q4 | -1.17 Million EUR | 17.95% |
2022 Q3 | -1.43 Million EUR | 8.67% |
2022 Q1 | -1.48 Million EUR | 28.09% |
2021 Q4 | -2.06 Million EUR | 0.0% |
2021 FY | - SEK | 16.32% |
2020 FY | - SEK | 38.17% |
2019 FY | - EUR | 16.73% |
2018 FY | - EUR | -73.4% |
2017 FY | - EUR | -6.1% |
2016 FY | - EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
SCHOTT Pharma AG & Co. KGaA | 227.64 Million EUR | 87.288% |
Carl Zeiss Meditec AG | 502.77 Million EUR | 94.244% |
Fielmann Aktiengesellschaft | 403.8 Million EUR | 92.834% |
Gerresheimer AG | 400.56 Million EUR | 92.776% |
Sartorius Aktiengesellschaft | 920.1 Million EUR | 96.855% |
Sartorius Aktiengesellschaft | 920.1 Million EUR | 96.855% |